Simultaneous quantification of IMPDH activity and purine bases in lymphocytes using LC-MS/MS: Assessment of biomarker responses to mycophenolic acid

Therapeutic Drug Monitoring

Volumn 36, Issue 1, 2014, Pages 108-118

  Vethe, Nils Tore ^a   Ali, Ali Mohamad ^a,b   Reine, Pal Aarstrand ^a   Andersen, Anders M ^a   Bremer, Sara ^a   Line, Pal Dag ^a   Rootwelt, Helge ^a   Bergan, Stein ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

IMPDH; LC MS MS; MPA; Mycophenolic acid; Purine bases

Indexed keywords

BIOLOGICAL MARKER; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PURINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; LIVER TRANSPLANTATION; LYMPHOCYTE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; TANDEM MASS SPECTROMETRY; TIME; YOUNG ADULT;

ADULT; AGED; BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; LIVER TRANSPLANTATION; LYMPHOCYTES; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PURINES; TANDEM MASS SPECTROMETRY; TIME FACTORS; YOUNG ADULT;

EID: 85027954875     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182a13900     Document Type: Article

References (31)

1. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation. 2005;80:S181-S190.
2. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13-58.
3. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007; 7:2496-2503.
4. Budde K, Bauer S, Hambach P, et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant. 2007;7:888-898.
5. Chiarelli LR, Molinaro M, Libetta C, et al. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-Term mycophenolate mofetil therapy. Br J Clin Pharmacol. 2010;69:38-50.
6. Fukuda T, Goebel J, Thogersen H, et al. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. J Clin Pharmacol. 2011;51:309-320.
7. Glander P, Hambach P, Braun KP, et al. Pre-Transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant. 2004;4:2045-2051.
8. Raggi MC, Siebert SB, Steimer W, et al. Customized mycophenolate dosing based on measuring inosine-monophosphate dehydrogenase activity significantly improves patients? outcomes after renal transplantation. Transplantation. 2010;90:1536-1541.
9. Vethe NT, Bremer S, Rootwelt H, et al. Pharmacodynamics of mycophenolic acid in CD4+ cells: A single-dose study of IMPDH and purine nucleotide responses in healthy individuals. Ther Drug Monit. 2008;30: 647-655.
10. Daxecker H, Raab M, Cichna M, et al. Determination of the effects of mycophenolic acid on the nucleotide pool of human peripheral blood mononuclear cells in vitro by high-performance liquid chromatography. Clin Chim Acta. 2001;310:81-87.
11. Qiu Y, Fairbanks LD, Ruckermann K, et al. Mycophenolic acid-induced GTP depletion also affects ATP and pyrimidine synthesis in mitogenstimulated primary human T-lymphocytes. Transplantation. 2000;69: 890-897.
12. Vethe NT, Bremer S, Bergan S. IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-Thioguanosine. Scand J Clin Lab Invest. 2007;68:1-9.
13. Jagodzinski P, Lizakowski S, Smolenski RT, et al. Mycophenolate mofetil treatment following renal transplantation decreases GTP concentrations in mononuclear leucocytes. Clin Sci (Lond). 2004;107:69-74.
14. Devyatko E, Zuckermann A, Bohdjalian A, et al. Activation of the purine salvage pathway in mononuclear cells of cardiac recipients treated with mycophenolate mofetil. Transplantation. 2006;82:113-118.
15. Albrecht W, Storck M, Pfetsch E, et al. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5?-monophosphate dehydrogenase in whole blood and isolated mononuclear cells. Ther Drug Monit. 2000; 22:283-294.
16. Glander P, Sombogaard F, Budde K, et al. Improved assay for the nonradioactive determination of inosine 5?-monophosphate dehydrogenase activity in peripheral blood mononuclear cells. Ther Drug Monit. 2009; 31:351-359.
17. Griesmacher A, Weigel G, Seebacher G, et al. IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide. Clin Chem. 1997;43:2312-2317.
18. Kalsi K, Marinaki AM, Yacoub MH, et al. HPLC/tandem ion trap mass detector methods for determination of inosine monophosphate dehydrogenase (IMPDH) and thiopurine methyltransferase (TPMT). Nucleosides Nucleotides Nucleic Acids. 2006;25:1241-1244.
19. Laverdiere I, Caron P, Couture F, et al. Liquid chromatography-coupled tandem mass spectrometry based assay to evaluate inosine-5?-monophosphate dehydrogenase activity in peripheral blood mononuclear cells from stem cell transplant recipients. Anal Chem. 2012;84:216-223.
20. Montero C, Duley JA, Fairbanks LD, et al. Demonstration of induction of erythrocyte inosine monophosphate dehydrogenase activity in Ribavirintreated patients using a high performance liquid chromatography linked method. Clin Chim Acta 1995;238:169-178.
21. Vethe NT, Bergan S. Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy. Ther Drug Monit. 2006;28:608-613.
22. Svensson JO, Brattstrom C, Sawe J. A simple HPLC method for simultaneous determination of mycophenolic acid and mycophenolic acid glucuronide in plasma. Ther Drug Monit. 1999;21:322-324.
23. Reine A, Vethe NT, Kongsgaard UE, et al. Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring. Scand J Clin Lab Invest. 2013;73:117-124.
24. Van Eeckhaut A, Lanckmans K, Sarre S, et al. Validation of bioanalytical LC-MS/MS assays: evaluation of matrix effects. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:2198-2207.
25. Dervieux T, Meyer G, Barham R, et al. Liquid chromatography-Tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy. Clin Chem. 2005;51:2074-2084.
26. Bremer S, Vethe NT, Rootwelt H, et al. Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients-A pilot study. J Transl Med. 2009;7:64.
27. Glander P, Sommerer C, Arns W, et al. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. Clin J Am Soc Nephrol. 2010;5:503-511.
28. Shah S, Harwood SM, Dohler B, et al. Inosine monophosphate dehydrogenase polymorphisms and renal allograft outcome. Transplantation. 2012;94:486-491.
29. Wang J, Yang JW, Zeevi A, et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther. 2008;83:711-717.
30. Pimkin M, Markham GD. The CBS subdomain of inosine 5?-monophosphate dehydrogenase regulates purine nucleotide turnover. Mol Microbiol. 2008;68:342-359.
31. Kozhevnikova EN, van der Knaap JA, Pindyurin AV, et al. Metabolic enzyme IMPDH is also a transcription factor regulated by cellular state. Mol Cell. 2012;47:133-139.